Omega Diagnostics Group Plc (LON:ODX) had its price objective upped by equities research analysts at FinnCap from GBX 28 ($0.36) to GBX 30 ($0.38) in a report released on Friday. The firm currently has a “corporate” rating on the stock. FinnCap’s price target would indicate a potential upside of 55.84% from the company’s previous close.

Omega Diagnostics Group Plc (ODX) traded up 15.06% during mid-day trading on Friday, hitting GBX 21.95. 20,620 shares of the stock were exchanged. The company’s 50-day moving average price is GBX 23.32 and its 200 day moving average price is GBX 20.70. Omega Diagnostics Group Plc has a 52 week low of GBX 15.12 and a 52 week high of GBX 28.01. The firm’s market capitalization is GBX 23.87 million.

COPYRIGHT VIOLATION NOTICE: “Omega Diagnostics Group Plc (ODX) Price Target Raised to GBX 30 at FinnCap” was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/06/30/omega-diagnostics-group-plc-odx-price-target-raised-to-gbx-30-at-finncap.html.

About Omega Diagnostics Group Plc

Omega Diagnostics Group PLC is a medical diagnostics company. The Company’s segments are Allergy and Autoimmune; Food Intolerance; Infectious/Other, and Corporate. Its product categories include allergy, anemia, autoimmunity, fertility and growth hormones, food intolerance, infectious disease, inflammation, quality control, thyroid hormones and tumor markers.

Receive News & Ratings for Omega Diagnostics Group Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omega Diagnostics Group Plc and related companies with MarketBeat.com's FREE daily email newsletter.